All In Biotech

Drug Trial Radar · NCT07112053

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

A Phase II Study of STEMVAC Vaccine Therapy for Patients With Hormone Receptor Positive Metastatic Breast Cancer

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Nov 17, 2025

Primary completion

Jul 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well a vaccine, STEMVAC, works in combination with standard endocrine-based therapy (ET) with a CDK4/6 targeted drug therapy, or with the chemotherapy drug capecitabine, in treating patients with hormone receptor (HR)-positive, HER2-negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic). STEMVAC is designed to target proteins that cancer cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Standard ET is treatment that adds, blocks, or removes hormones in order to slow or stop the growth of cancer. Standard CDK4/6 inhibitors, including abemaciclib, may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Giving STEMVAC in combination with standard ET or chemotherapy may be an effective treatment for metastatic HR positive, HER2 negative breast cancer.

Conditions

  • Anatomic Stage IV Breast Cancer AJCC v8
  • Metastatic HER2-Negative Breast Carcinoma
  • Metastatic Hormone Receptor-Positive Breast Carcinoma

Interventions

  • CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA VaccineBiological

    Given ID

  • CapecitabineDrug

    Given SOC capecitabine

  • Computed TomographyProcedure

    Undergo CT or ultrasound-guided biopsies

  • Cyclin-Dependent Kinase 4 InhibitorDrug

    Given SOC CDK4/6i

  • Cyclin-Dependent Kinase 6 InhibitorDrug

    Given SOC CDK4/6i

  • F-18 16 Alpha-FluoroestradiolDrug

    Undergo FES PET

  • Hormone TherapyDrug

    Given SOC ET

  • Positron Emission TomographyProcedure

    Undergo PET or FES PET

  • Biopsy ProcedureProcedure

    Undergo image-guided biopsies

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • AbemaciclibDrug

    Given SOC abemaciclib

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: Up to 3 years after completion of study treatment
  2. Incidence of immunogenicityTime frame: Pre-vaccine up to after 2 booster doses of STEMVAC vaccine (Up to 40 weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fred Hutch/University of Washington Cancer Consortium

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.